Bruttomesso D, Petrie JR, Evans M, et al. Challenges in and opportunities for individualizing diabetes technology: a position statement by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. Diabetes Care. 2026;49(6):916-930.
Fleming GA, Mathieu C, Skyler JS. The importance of C-peptide for developing T1D disease-modifying therapies. Diabetes Care. Published online April 20, 2026.
Muchmore DB, Calhoun P, Heinemann L. Letter: Hypoglycemia assessed by continuous glucose monitoring: a proposal to define the end of a hypoglycemic event more precisely. Diabetes Technol Ther. Published online February 11, 2026.
Barbut D, Kinney WA, Chen HH, et al. A novel, centrally acting mammalian aminosterol, ENT-03, induces weight loss in obese and lean rodents. Diabetes Obes Metab. 2024;26(12):5701-5712.
Biomarkers of Aging Consortium, Herzog CMS, Goeminne LJE, et al. Challenges and recommendations for the translation of biomarkers of aging. Nat Aging. 2024;4(10):1372-1383.
Jendle J, Adolfsson P, Choudhary P, et al. A narrative commentary about interoperability in medical devices and data used in diabetes therapy from an academic EU/UK/US perspective. Diabetologia. 2024;67(2):236-245.
Klonoff DC, Wang J, Rodbard D, et al. A glycemia risk index (GRI) of hypoglycemia and hyperglycemia for continuous glucose monitoring validated by clinician ratings. J Diabetes Sci Technol. 2023;17(5):1226-1242.
Sherr JL, Heinemann L, Fleming GA, et al. Automated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association. Diabetologia. 2023;66(1):3-22.
Muchmore DB. Regarding: Insulin infusion set failures. Diabetes Technol Ther. 2022;24(8):599-600.
Lebovitz HE, Fleming A, Cherrington AD, et al. Efficacy and safety of Tregopil, a novel, ultra-rapid acting oral prandial insulin analog, as part of a basal-bolus regimen in type 2 diabetes: a randomized, active-controlled phase 2/3 study. Expert Opin Pharmacother. 2022;23(16):1855-1863.
Eldor R, Francis BH, Fleming A, et al. Oral insulin (ORMD-0801) in type 2 diabetes mellitus: a dose-finding 12-week randomized placebo-controlled study. Diabetes Obes Metab. 2023;25(4):943-952.
Schreyer E, Obringer C, Messaddeq N, et al. PATAS, a first-in-class therapeutic peptide biologic, improves whole-body insulin resistance and associated comorbidities in vivo. Diabetes. 2022;71(9):2034-2047.
Klonoff DC, Fleming A, Gabbay R. The need to change regulatory evaluation of hypoglycemia in trials of diabetes treatments. J Diabetes Sci Technol. 2020;14(6):987-989.
Klonoff DC, Florez JC, German M, Fleming A. The need for precision medicine to be applied to diabetes. J Diabetes Sci Technol. 2020;14(6):1122-1128.
Klonoff DC, Gutierrez A, Fleming A, Kerr D. Real-world evidence should be used in regulatory decisions about new pharmaceutical and medical device products for diabetes. J Diabetes Sci Technol. 2019;13(6):995-1000.
Fleming GA, Petrie JR, Bergenstal RM, Holl RW, Peters AL, Heinemann L. Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. Diabetologia. 2020;63(2):229-241.
Fleming GA, Zhao JH, Seoh TC, Barzilai N. A regulatory pathway for medicines that target aging. Public Policy Aging Rep. 2019;29(4):128-133
Irl BH, Evert A, Fleming A, et al. Culinary medicine: advancing a framework for gealthier eating to improve chronic disease management and prevention. Clin Ther. 2019;41(10):2184-2198.
Klonoff DC, Gutierrez A, Fleming A, Kerr D. Real-world evidence should be used in regulatory decisions about new pharmaceutical and medical device products for diabetes. J Diabetes Sci Technol. 2019;13(6):995-1000.
Fleming GA, Harvey BE. Regulatory considerations for early clinical development of drugs for diabetes, obesity, nonalcoholic steatohepatitis (NASH) and other cardiometabolic disorders. In: Krentz AJ, Weyer C, Hompesch M, eds. Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease. Springer; 2019:487-515.
Khedkar A, Lebovitz H, Fleming A, et al. Impact of insulin tregopil and its permeation enhancer on pharmacokinetics of metformin in healthy volunteers: randomized, open-label, placebo-controlled, crossover study. Clin Transl Sci. 2019;12(3):276-282.